Tennessee 2023-2024 Regular Session

Tennessee House Bill HB2308

Introduced
1/29/24  
Refer
2/1/24  
Refer
3/12/24  
Refer
3/20/24  
Chaptered
5/13/24  

Caption

AN ACT to amend Tennessee Code Annotated, Title 33; Title 53; Title 63 and Title 68, relative to the use of buprenorphine products.

Impact

The implications of HB 2308 on state laws include a significant shift in how buprenorphine is prescribed, aiming to centralize authority within the medical community. By limiting prescribing rights, the bill aims to enhance the quality of care for patients undergoing treatment for opioid use disorder. However, this legislation may lead to challenges for patients seeking access to treatment, especially in rural areas where specialists may be scarce. Therefore, while aiming to improve patient safety, it also risks inadvertently limiting access to necessary recovery resources for some individuals.

Summary

House Bill 2308 aims to regulate the prescribing of buprenorphine products in Tennessee, particularly for the treatment of opioid use disorder. The legislation specifies that only physicians licensed under specific chapters can prescribe these medications for approved uses in recovery or medication-assisted treatment. Notably, certain healthcare providers such as nurse practitioners and physician assistants are restricted from prescribing buprenorphine unless they meet stringent conditions related to their employment, training, and supervision. This targeted approach seeks to ensure that only adequately trained professionals can provide prescriptions to patients dealing with opioid addiction, thereby addressing potential misuse while promoting safe treatment protocols.

Sentiment

The general sentiment surrounding HB 2308 appears to be mixed. Proponents argue that the bill is a positive step towards ensuring that those with the necessary training provide treatment, which will likely enhance patient safety and treatment outcomes. However, opponents raise concerns regarding potential barriers that could arise from these restrictions, particularly the impact on existing patients who may face difficulties in accessing their prescriptions. The discussion reflects a balance between the imperative to regulate treatment responsibly and the need to ensure patient access to vital medications.

Contention

Points of contention related to HB 2308 focus on the constraints placed on non-physician healthcare providers. Critics argue that the bill overemphasizes regulation at the expense of patient care, potentially limiting the capacity for various qualified healthcare professionals to help manage opioid addiction effectively. Additionally, there are ongoing discussions about the adequacy of training and resources available to meet the demands of this law, particularly in underserved communities where access to healthcare may already be limited.

Companion Bills

TN SB2297

Crossfiled AN ACT to amend Tennessee Code Annotated, Title 33; Title 53; Title 63 and Title 68, relative to the use of buprenorphine products.

Similar Bills

NJ SCR54

Urges U.S. President, Congress, and Department of Health and Human Services to ease patient limits applicable to private physicians prescribing buprenorphine as part of medication-assisted treatment for substance use disorders.

NJ A3668

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

NJ A2544

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

NJ S2143

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

HI HB816

Relating To Emergency Response.

HI SB851

Relating To Emergency Response.

CA AB1842

Health care coverage: Medication-assisted treatment.

MD HB1131

Public Health - Buprenorphine - Training Grant Program and Workgroup